Clinical Trials
Clinical trial of antiviral for monkeypox goes forward as cases decline
Experts involved with an NIH trial of tecovirimat said that even as cases of monkeypox continue to decline nationally, it is important to establish whether the antiviral is effective against the infection.
Positive results shown in ongoing phase 2 trial of cannabinoid intoxication treatment
A biopharmaceutical company has announced positive interim data from the first two cohorts in an ongoing phase 2 clinical trial of its treatment for acute cannabinoid intoxication.
Biomind completes dosing in phase 2 trial of inhaled therapeutic for TRD
Biomind Labs Inc. announced the completion of dose administration to 30 healthy participants in the phase 2 trial of its novel inhaled formulation, BMND01, to address treatment-resistant depression.
Phase 2a cognition, dementia treatment trial underway
CuraSen Therapeutics Inc. announced it has begun dosing patients in a phase 2a clinical trial with CST-2032, an oral therapeutic for treatment of mild cognitive impairment or mild dementia due to either Parkinson’s or Alzheimer’s disease.
FDA advisory committee votes to support approval of ALS therapy
Amylyx Pharmaceuticals announced that the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee voted to support approval of the company’s oral, fixed-dose therapeutic AMX0035 for the treatment of ALS.
Positive interim results announced in study of therapeutic for Becker muscular dystrophy
Edgewise Therapeutics Inc. announced positive 4-month interim results from the ongoing ARCH study of investigational, orally administered EDG-5506 for the treatment of Becker muscular dystrophy in adults.
Vistagen to continue phase 3 clinical trial of social anxiety treatment
Vistagen Therapeutics announced the completion of an interim analysis of PALISADE-2, the company’s second phase 3 clinical trial assessing PH94B in adults with social anxiety disorder, and concluded the trial should continue as planned.
Cancer clinical trials enrolling larger proportion of adolescents, young adults
Younger patients with newly diagnosed cancer are comprising a larger proportion of participants in phase 2 and phase 3 clinical trials for treatments, research published in the journal Cancer showed.
Ketamine may be effective in treating children with ADNP syndrome
Low-dose ketamine was generally safe, well-tolerated and effective in treating clinical symptoms in a small group of children with activity-dependent neuroprotective protein syndrome, researchers reported.
MindMed announces initial patient dosing in phase 2b trial of LSD-based anxiety treatment
A biopharmaceutical company has announced the first patient dosing in its phase 2b dose-optimization trial of MM-120, a form of lysergic acid diethylamide utilized for the treatment of generalized anxiety disorder.